NeoGenomics Inc (STU:NG9)

€ 12.6 -0.1 (-0.79%) Market Cap: 1.76 Bil Enterprise Value: 1.96 Bil PE Ratio: 0 PB Ratio: 1.97 GF Score: 76/100

Q3 2024 Neogenomics Inc Earnings Call Transcript
23 hours ago

€12.6 (-0.79%)

Earnings
Q2 2024 Neogenomics Inc Earnings Call Transcript
Jul 29, 2024

€13.4 (-2.19%)

Earnings
Q1 2024 Neogenomics Inc Earnings Call Transcript
Apr 30, 2024

€14.2 (+9.23%)

Earnings
Q4 2023 Neogenomics Inc Earnings Call Transcript
Feb 20, 2024

€12.9 (-0.77%)

Earnings
Neogenomics Inc at JPMorgan Healthcare Conference Transcript
Jan 09, 2024
Q3 2023 Neogenomics Inc Earnings Call Transcript
Nov 06, 2023

€13.5 (-4.26%)

Earnings
Q2 2023 Neogenomics Inc Earnings Call Transcript
Aug 08, 2023

€13.3 (-4.32%)

Earnings
Neogenomics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Neogenomics Inc at Bank of America Global Healthcare Conference Transcript
May 10, 2023
Q1 2023 Neogenomics Inc Earnings Call Transcript
May 08, 2023

€13.9 (+2.21%)

Earnings
Neogenomics Inc Investor Day Transcript
Apr 04, 2023
Q4 2022 Neogenomics Inc Earnings Call Transcript
Feb 23, 2023

€12.4 (+2.11%)

Earnings
Q3 2022 Neogenomics Inc Earnings Call Transcript
Nov 08, 2022

€6.98 (-3.19%)

Earnings
Q2 2022 Neogenomics Inc Earnings Call Transcript
Aug 09, 2022

€9.72 (-0.54%)

Earnings
Neogenomics Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Q1 2022 Neogenomics Inc Earnings Call Transcript
Apr 27, 2022

€10.33 (-2.86%)

Earnings
Neogenomics Inc at Raymond James Institutional Investors Conference Transcript
Mar 07, 2022
Q4 2021 Neogenomics Inc Earnings Call Transcript
Feb 23, 2022

€16.44 (+0.34%)

Earnings
Q3 2021 Neogenomics Inc Earnings Call Transcript
Nov 04, 2021

€39.42 (+0.51%)

Earnings
Q2 2021 Neogenomics Inc Earnings Call Transcript
Aug 06, 2021

€39.04 (-1.24%)

Earnings
Neogenomics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Neogenomics Inc Annual Shareholders Meeting Transcript
May 27, 2021
Q1 2021 Neogenomics Inc Earnings and to Discuss Acquisition of Inivata Ltd Call Transcript
May 05, 2021
Q4 2020 Neogenomics Inc Earnings Call Transcript
Feb 24, 2021

€42 (-1.41%)

Earnings
Neogenomics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Q3 2020 Neogenomics Inc Earnings Call Transcript
Oct 27, 2020

€35 (+1.16%)

Earnings
Neogenomics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Q2 2020 Neogenomics Inc Earnings Call Transcript
Jul 28, 2020

€30.8 (+1.32%)

Earnings
Neogenomics Inc Annual Shareholders Meeting Transcript
May 28, 2020
Q1 2020 Neogenomics Inc Earnings Call Transcript
Apr 28, 2020

€25.4 (-5.93%)

Earnings
Q4 2019 Neogenomics Inc Earnings Call Transcript
Feb 27, 2020

€26 (-5.11%)

Earnings
Q3 2019 Neogenomics Inc Earnings Call Transcript
Oct 29, 2019

€18.4 (-0.54%)

Earnings
Neogenomics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Q2 2019 Neogenomics Inc Earnings Call Transcript
Jul 30, 2019

€20.86 (+0.26%)

Earnings
Q1 2019 Neogenomics Inc Earnings Call Transcript
Apr 30, 2019

€18.22 (-1.52%)

Earnings
Neogenomics Inc at Cowen Health Care Conference Transcript
Mar 12, 2019
Q4 2018 Neogenomics Inc Earnings Call Transcript
Feb 19, 2019

€15.17 (-2.07%)

Earnings

Neogenomics Inc at Bank of America Healthcare Conference Transcript

May 12, 2022 / 04:20PM GMT

Release Date Price: €6.83 (-6.88%)

Transcript 10-Q

Derik De Bruin

BofA Securities, Research Division - MD of Equity Research

Good morning, everyone. Welcome to Bank of America's 2022 Healthcare Conference coming to you live from Las Vegas. I'm Derik De Bruin, the Senior Life Sciences and Diagnostic tools analyst from Bank of America. And it is our pleasure to kick off this morning with NeoGenomics.

With me today are Charlie Eidson, IR and Bill Bonello, Chief Financial Officer. Gentlemen, thank you for being here.

William Bishop Bonello

NeoGenomics, Inc. - CFO

Thanks for having us.

Questions & Answers

Derik De Bruin

BofA Securities, Research Division - MD of Equity Research

So get running into it, NEO's had a little bit of rough start in 2022. Your guidance in the summer mutes the management team have transitioned, you've put your hiring plans to hold cost structures and issues, a lot to unpack here. So I think the first question is like why do you think Neo's core business hasn't bounced back as the COVID headwinds have eased like some of the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.